+

WO2006048665A3 - Composes chimiques - Google Patents

Composes chimiques Download PDF

Info

Publication number
WO2006048665A3
WO2006048665A3 PCT/GB2005/004266 GB2005004266W WO2006048665A3 WO 2006048665 A3 WO2006048665 A3 WO 2006048665A3 GB 2005004266 W GB2005004266 W GB 2005004266W WO 2006048665 A3 WO2006048665 A3 WO 2006048665A3
Authority
WO
WIPO (PCT)
Prior art keywords
sarsapogenin
polymorphs
sarsasapogenin
solvated
crystalline
Prior art date
Application number
PCT/GB2005/004266
Other languages
English (en)
Other versions
WO2006048665A2 (fr
Inventor
Peter David Tiffin
Original Assignee
Phytopharm Plc
Peter David Tiffin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0517648-4A priority Critical patent/BRPI0517648A/pt
Priority to AU2005300348A priority patent/AU2005300348A1/en
Priority to US11/667,035 priority patent/US20080194530A1/en
Priority to CA002584676A priority patent/CA2584676A1/fr
Priority to JP2007539637A priority patent/JP2008519020A/ja
Priority to EP05799915A priority patent/EP1809650A2/fr
Priority to RU2007119611/04A priority patent/RU2007119611A/ru
Application filed by Phytopharm Plc, Peter David Tiffin filed Critical Phytopharm Plc
Priority to MX2007005473A priority patent/MX2007005473A/es
Priority to CN200580037705XA priority patent/CN101068827B/zh
Publication of WO2006048665A2 publication Critical patent/WO2006048665A2/fr
Publication of WO2006048665A3 publication Critical patent/WO2006048665A3/fr
Priority to IL182879A priority patent/IL182879A0/en
Priority to NO20072794A priority patent/NO20072794L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Virology (AREA)

Abstract

L'invention concerne de la sarsasapogénine sous de nouvelles formes amorphes, cristallines, solvatées et hydratées, ainsi que l'utilisation de ces formes dans la fabrication de sarsasapogénine pharmaceutique ou comestible et de ses dérivés.
PCT/GB2005/004266 2004-11-05 2005-11-04 Composes chimiques WO2006048665A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2007005473A MX2007005473A (es) 2004-11-05 2005-11-04 Compuestos quimicos.
US11/667,035 US20080194530A1 (en) 2004-11-05 2005-11-04 Chemical Compounds
CA002584676A CA2584676A1 (fr) 2004-11-05 2005-11-04 Composes chimiques
JP2007539637A JP2008519020A (ja) 2004-11-05 2005-11-04 サルササポゲニンの多形相
EP05799915A EP1809650A2 (fr) 2004-11-05 2005-11-04 Polymorphes de la sarsapogenine
BRPI0517648-4A BRPI0517648A (pt) 2004-11-05 2005-11-04 compostos quìmicos
AU2005300348A AU2005300348A1 (en) 2004-11-05 2005-11-04 Polymorphs of sarsapogenin
RU2007119611/04A RU2007119611A (ru) 2004-11-05 2005-11-04 Полиморфы сарсасапогенина
CN200580037705XA CN101068827B (zh) 2004-11-05 2005-11-04 萨洒皂草配基的多晶型物
IL182879A IL182879A0 (en) 2004-11-05 2007-04-30 Polymorphs of sarsapogenin
NO20072794A NO20072794L (no) 2004-11-05 2007-06-01 Kjemiske forbindelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0424528A GB0424528D0 (en) 2004-11-05 2004-11-05 Chemical compounds
GB0424528.8 2004-11-05

Publications (2)

Publication Number Publication Date
WO2006048665A2 WO2006048665A2 (fr) 2006-05-11
WO2006048665A3 true WO2006048665A3 (fr) 2006-09-08

Family

ID=33523268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004266 WO2006048665A2 (fr) 2004-11-05 2005-11-04 Composes chimiques

Country Status (17)

Country Link
US (1) US20080194530A1 (fr)
EP (2) EP1809650A2 (fr)
JP (1) JP2008519020A (fr)
KR (1) KR20070089798A (fr)
CN (2) CN101068827B (fr)
AU (1) AU2005300348A1 (fr)
BR (1) BRPI0517648A (fr)
CA (1) CA2584676A1 (fr)
GB (1) GB0424528D0 (fr)
IL (1) IL182879A0 (fr)
MX (1) MX2007005473A (fr)
NO (1) NO20072794L (fr)
RU (1) RU2007119611A (fr)
SG (1) SG158068A1 (fr)
TW (1) TW200635941A (fr)
WO (1) WO2006048665A2 (fr)
ZA (1) ZA200703630B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515754A (ja) 2009-01-24 2012-07-12 ファイトファーム ピーエルシー 神経栄養因子介在疾患の治療
SG187090A1 (en) 2010-07-20 2013-02-28 Phytopharm Plc Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
JP5881525B2 (ja) * 2011-05-16 2016-03-09 ライオン株式会社 サポゲニン安定化組成物の製造方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2306635A (en) * 1940-08-03 1942-12-29 Parke Davis & Co Method for the preparation of steroidal carbinols
US2408827A (en) * 1944-05-15 1946-10-08 Parke Davis & Co Steroidal compounds and methods for obtaining the same
US2774714A (en) * 1952-10-10 1956-12-18 Emanuel B Hershberg Process for the extraction of sapogenins from plant materials
US3019220A (en) * 1958-07-17 1962-01-30 Julian Lab Inc Isolation of sapogenins
US4057543A (en) * 1976-07-01 1977-11-08 G. D. Searle & Co. Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone
EP0204661A2 (fr) * 1985-06-05 1986-12-10 Progenics, Inc. Compositions contenant des sapogénines pour le traitement de l'obésité et diabète
CN1096031C (zh) * 1996-12-23 2002-12-11 三星电子株式会社 打印头喷嘴间距的补偿装置和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04230696A (ja) * 1990-12-28 1992-08-19 Sanwa Shiyouyaku Kk 新規なステロイド系化合物および制癌剤
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
KR100632052B1 (ko) 1998-03-26 2006-10-04 파이토팜 피엘씨 알츠하이머병을 치료하기 위한 스테로이드계 사포게닌 및 이의 유도체
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
AT409100B (de) 2000-07-24 2002-05-27 Evg Entwicklung Verwert Ges Vorrichtung zum schweissen einer drahtgittermatte
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
CN1642558B (zh) * 2002-03-27 2012-05-30 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2306635A (en) * 1940-08-03 1942-12-29 Parke Davis & Co Method for the preparation of steroidal carbinols
US2408827A (en) * 1944-05-15 1946-10-08 Parke Davis & Co Steroidal compounds and methods for obtaining the same
US2774714A (en) * 1952-10-10 1956-12-18 Emanuel B Hershberg Process for the extraction of sapogenins from plant materials
US3019220A (en) * 1958-07-17 1962-01-30 Julian Lab Inc Isolation of sapogenins
US4057543A (en) * 1976-07-01 1977-11-08 G. D. Searle & Co. Process for the preparation of 17β-hydroxy-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone
EP0204661A2 (fr) * 1985-06-05 1986-12-10 Progenics, Inc. Compositions contenant des sapogénines pour le traitement de l'obésité et diabète
CN1096031C (zh) * 1996-12-23 2002-12-11 三星电子株式会社 打印头喷嘴间距的补偿装置和方法

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CANDELA J L F ET AL: "NEUVA FUENTE DE SARSAPOGENINA NEW SOURCE OF SARSAPOGENIN", ANALES DE LA REAL SOCIEDAD ESPANOLA DE FISICA Y QUIMICA, SERIE B: QUIMICA, MADRID, ES, 1951, pages 309 - 311, XP008043213, ISSN: 0034-088X *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; RABASSA, ROGER ET AL: "Sarsapogenin. Extraction from asparagus", XP002318343, retrieved from STN Database accession no. 1954:25095 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YI, NINGYU ET AL: "Extraction of .beta.-adrenergic receptor- and M cholinergic receptor-regulating (.beta.,5.beta.,25s)-spirostan-3-ol from Anemarrhena asphodeloides Bunge", XP002369130, retrieved from STN Database accession no. 1995:881491 *
DING ET AL: "Study on the Yin-tonic component of the Chinese herb Zhimu: sarsasapogenin", CAPLUS, 1991, XP002157712 *
J. SIMPSON ET AL: "SARSASAPOGENIN. ii.", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol. 109, 1935, USAMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., pages 573 - 584, XP002318340 *
MARKER R E ET AL: "Steroidal Sapogenins", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 69, no. 9, 25 September 1947 (1947-09-25), pages 2167 - 2230, XP002157706, ISSN: 0002-7863 *
R. MARKER ET AL: "Sterols. CVII. Steroidal Sapogenins of Aletris, Asparagus and Lilium", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 62, 1940, USAMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., pages 2620 - 2621, XP002318341 *
REV. ASOC. BIOQUIM. ARGENTINA ( 1953 ), 18, 33-4, 1953 *
W. BEHER ET AL: "X-Ray Difffraction Powder Data for the Steroids", ANALYTICAL CHEMISTRY., vol. 27, no. 10, 1955, USAMERICAN CHEMICAL SOCIETY. COLUMBUS., pages 1569 - 1573, XP002318342 *
WALL M E ET AL: "Steroidal Sapogenins. XXVII. Preparation and Properties of 20-Isosapogenins", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 77, 1955, pages 5661 - 5665, XP002293039, ISSN: 0002-7863 *
WAWER I ET AL: "13C cross-polarization MAS NMR study of some steroidal sapogenins.", SOLID STATE NUCLEAR MAGNETIC RESONANCE. 2001 AUG-SEP, vol. 20, no. 1-2, August 2001 (2001-08-01), pages 35 - 45, XP002388162, ISSN: 0926-2040 *
YI N ET AL: "Sarsasapogenin: Mechanism in treating senile dementia", SYNTHESIS AND APPLICATIONS OF ISOTOPICALLY LABELLED COMPOUNDS, XX, XX, 14 September 1997 (1997-09-14), pages 315 - 320, XP002117140 *

Also Published As

Publication number Publication date
GB0424528D0 (en) 2004-12-08
CN101068827A (zh) 2007-11-07
EP1809650A2 (fr) 2007-07-25
IL182879A0 (en) 2007-08-19
CN102219826A (zh) 2011-10-19
KR20070089798A (ko) 2007-09-03
CA2584676A1 (fr) 2006-05-11
EP2479183A3 (fr) 2013-08-28
AU2005300348A1 (en) 2006-05-11
BRPI0517648A (pt) 2008-10-14
MX2007005473A (es) 2007-05-24
ZA200703630B (en) 2009-10-28
US20080194530A1 (en) 2008-08-14
TW200635941A (en) 2006-10-16
JP2008519020A (ja) 2008-06-05
EP2479183A2 (fr) 2012-07-25
NO20072794L (no) 2007-07-31
RU2007119611A (ru) 2008-12-10
WO2006048665A2 (fr) 2006-05-11
SG158068A1 (en) 2010-01-29
CN101068827B (zh) 2011-06-08

Similar Documents

Publication Publication Date Title
EP1784267A4 (fr) Endoprothese coronaire et procede de fabrication de l'endoprothese coronaire
IL174952A0 (en) Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
WO2006023627A8 (fr) Polymorphes de rapamycine et leurs utilisations
IL179758A (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
WO2008066935A3 (fr) Formes cristallines de tigécycline et procédés de préparation de celles-ci
WO2008035373A3 (fr) Acide polysialique hautement pur et procédé d'élaboration
WO2009025876A8 (fr) Formes cristallines de chlorhydrate d'erlotinib et formulations de celles-ci
WO2008021342A3 (fr) Formes cristallines de la 9-hydroxy-rispéridone (palipéridone)
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
WO2006073939A3 (fr) 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphtyridin-4-amine ethanesulfonate et 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphtyridin-4-amine methanesulfonate
EP1773788B8 (fr) Dérivés de quinazoline
WO2006034451A3 (fr) Bromhydrate de clopidogrel cristallin et procede de preparation correspondant
WO2008157563A3 (fr) Clopidogrel enrichi en deutérium
WO2005016325A3 (fr) Chlorhydrate de ziprasidone cristallin et ses procedes de preparation
WO2005102999A3 (fr) Formes cristallines d'hydrochlorure de fexofenadine, et procedes pour les preparer
WO2006048665A3 (fr) Composes chimiques
WO2005105825A3 (fr) Composes chimiques
WO2008021518A3 (fr) Formes cristallines d'hydrochlorure de tiagabine
EP1810976B8 (fr) Dérivé de benzonaphthacèneglycoside et utilisation dudit dérivé
WO2006077584A3 (fr) Nouvelles formes cristallines d'aripiprazole
AU2006315663A8 (en) KIFS as modifiers of the RHO pathway and methods of use
WO2008157562A3 (fr) Olanzapine enrichie en deutérium
AU2004904337A0 (en) Tommychock-safety chock
AU2004903247A0 (en) Cart-wheel chock
PL375287A1 (pl) Nowa pochodna izoksazolo[4,5-d]pirymidyny i sposób wytwarzania nowej pochodnej izoksazolo[4,5-d]pirymidyny

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005799915

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2584676

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 554733

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200580037705.X

Country of ref document: CN

Ref document number: 182879

Country of ref document: IL

Ref document number: 2005300348

Country of ref document: AU

Ref document number: 626/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007539637

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005473

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12007501069

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2005300348

Country of ref document: AU

Date of ref document: 20051104

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007119611

Country of ref document: RU

Ref document number: 07056924

Country of ref document: CO

Ref document number: 1020077012720

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005799915

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11667035

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0517648

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载